Replies to post #165351 on Biotech Values

[DewDiligence]

It looks like FRX is going to be late to market with its LAMA/LABA combination. Not good for the commercial prospects insofar as FRX’s product does not seem well differentiated from the products offered by NVS and GSK/THRX.